Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.
Market Analysis and Insights: Global Fabry Disease Treatment Market
The research report studies the Fabry Disease Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Fabry Disease Treatment market size is projected to reach US$ 2171.1 million by 2026, from US$ 1579.6 million in 2020, at a CAGR of 5.4% during 2021-2026.
Global Fabry Disease Treatment Scope and Segment
The global Fabry Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Fabry Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)
Others
by Application, this report covers the following segments
Hospital
Clinic
Others
Global Fabry Disease Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Fabry Disease Treatment key players in this market include:
Sanofi S.A.
Takeda
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Greenovation Biotech GmbH
Moderna Therapeutics Inc.
Green Cross Pharma Pte Ltd.
Market Analysis and Insights: Global Fabry Disease Treatment Market
The research report studies the Fabry Disease Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Fabry Disease Treatment market size is projected to reach US$ 2171.1 million by 2026, from US$ 1579.6 million in 2020, at a CAGR of 5.4% during 2021-2026.
Global Fabry Disease Treatment Scope and Segment
The global Fabry Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Fabry Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)
Others
by Application, this report covers the following segments
Hospital
Clinic
Others
Global Fabry Disease Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Fabry Disease Treatment key players in this market include:
Sanofi S.A.
Takeda
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Greenovation Biotech GmbH
Moderna Therapeutics Inc.
Green Cross Pharma Pte Ltd.
1 Market Overview of Fabry Disease Treatment
1.1 Fabry Disease Treatment Market Overview
1.1.1 Fabry Disease Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Global Fabry Disease Treatment Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Fabry Disease Treatment Market Size by Region (2015-2026)
1.4 Global Fabry Disease Treatment Historic Market Size by Region (2015-2020)
1.5 Global Fabry Disease Treatment Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.1 North America Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.2 Europe Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.4 Latin America Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Fabry Disease Treatment Market Size YoY Growth (2015-2026)
2 Fabry Disease Treatment Market Overview by Type
2.1 Global Fabry Disease Treatment Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Fabry Disease Treatment Historic Market Size by Type (2015-2020)
2.3 Global Fabry Disease Treatment Forecasted Market Size by Type (2021-2026)
2.4 Enzyme Replacement Therapy (ERT)
2.5 Chaperone Treatment
2.6 Substrate Reduction Therapy (SRT)
2.7 Others
3 Fabry Disease Treatment Market Overview by Application
3.1 Global Fabry Disease Treatment Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Fabry Disease Treatment Historic Market Size by Application (2015-2020)
3.3 Global Fabry Disease Treatment Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Others
4 Global Fabry Disease Treatment Competition Analysis by Players
4.1 Global Fabry Disease Treatment Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fabry Disease Treatment as of 2019)
4.3 Date of Key Manufacturers Enter into Fabry Disease Treatment Market
4.4 Global Top Players Fabry Disease Treatment Headquarters and Area Served
4.5 Key Players Fabry Disease Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Fabry Disease Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi S.A.
5.1.1 Sanofi S.A. Profile
5.1.2 Sanofi S.A. Main Business
5.1.3 Sanofi S.A. Fabry Disease Treatment Products, Services and Solutions
5.1.4 Sanofi S.A. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.1.5 Sanofi S.A. Recent Developments
5.2 Takeda
5.2.1 Takeda Profile
5.2.2 Takeda Main Business
5.2.3 Takeda Fabry Disease Treatment Products, Services and Solutions
5.2.4 Takeda Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.2.5 Takeda Recent Developments
5.3 Amicus Therapeutics Inc.
5.5.1 Amicus Therapeutics Inc. Profile
5.3.2 Amicus Therapeutics Inc. Main Business
5.3.3 Amicus Therapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.3.4 Amicus Therapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.3.5 ISU Abxis Co Ltd. Recent Developments
5.4 ISU Abxis Co Ltd.
5.4.1 ISU Abxis Co Ltd. Profile
5.4.2 ISU Abxis Co Ltd. Main Business
5.4.3 ISU Abxis Co Ltd. Fabry Disease Treatment Products, Services and Solutions
5.4.4 ISU Abxis Co Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.4.5 ISU Abxis Co Ltd. Recent Developments
5.5 JCR Pharmaceuticals Co Ltd.
5.5.1 JCR Pharmaceuticals Co Ltd. Profile
5.5.2 JCR Pharmaceuticals Co Ltd. Main Business
5.5.3 JCR Pharmaceuticals Co Ltd. Fabry Disease Treatment Products, Services and Solutions
5.5.4 JCR Pharmaceuticals Co Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.5.5 JCR Pharmaceuticals Co Ltd. Recent Developments
5.6 Protalix Biotherapeutics Inc.
5.6.1 Protalix Biotherapeutics Inc. Profile
5.6.2 Protalix Biotherapeutics Inc. Main Business
5.6.3 Protalix Biotherapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.6.4 Protalix Biotherapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.6.5 Protalix Biotherapeutics Inc. Recent Developments
5.7 Idorsia Pharmaceuticals Ltd.
5.7.1 Idorsia Pharmaceuticals Ltd. Profile
5.7.2 Idorsia Pharmaceuticals Ltd. Main Business
5.7.3 Idorsia Pharmaceuticals Ltd. Fabry Disease Treatment Products, Services and Solutions
5.7.4 Idorsia Pharmaceuticals Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.7.5 Idorsia Pharmaceuticals Ltd. Recent Developments
5.8 Avrobio Inc.
5.8.1 Avrobio Inc. Profile
5.8.2 Avrobio Inc. Main Business
5.8.3 Avrobio Inc. Fabry Disease Treatment Products, Services and Solutions
5.8.4 Avrobio Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.8.5 Avrobio Inc. Recent Developments
5.9 Greenovation Biotech GmbH
5.9.1 Greenovation Biotech GmbH Profile
5.9.2 Greenovation Biotech GmbH Main Business
5.9.3 Greenovation Biotech GmbH Fabry Disease Treatment Products, Services and Solutions
5.9.4 Greenovation Biotech GmbH Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.9.5 Greenovation Biotech GmbH Recent Developments
5.10 Moderna Therapeutics Inc.
5.10.1 Moderna Therapeutics Inc. Profile
5.10.2 Moderna Therapeutics Inc. Main Business
5.10.3 Moderna Therapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.10.4 Moderna Therapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.10.5 Moderna Therapeutics Inc. Recent Developments
5.11 Green Cross Pharma Pte Ltd.
5.11.1 Green Cross Pharma Pte Ltd. Profile
5.11.2 Green Cross Pharma Pte Ltd. Main Business
5.11.3 Green Cross Pharma Pte Ltd. Fabry Disease Treatment Products, Services and Solutions
5.11.4 Green Cross Pharma Pte Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.11.5 Green Cross Pharma Pte Ltd. Recent Developments
6 North America
6.1 North America Fabry Disease Treatment Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Fabry Disease Treatment Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Fabry Disease Treatment Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Fabry Disease Treatment Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Fabry Disease Treatment Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Fabry Disease Treatment Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Fabry Disease Treatment Market Overview
1.1.1 Fabry Disease Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Global Fabry Disease Treatment Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Fabry Disease Treatment Market Size by Region (2015-2026)
1.4 Global Fabry Disease Treatment Historic Market Size by Region (2015-2020)
1.5 Global Fabry Disease Treatment Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.1 North America Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.2 Europe Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.4 Latin America Fabry Disease Treatment Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Fabry Disease Treatment Market Size YoY Growth (2015-2026)
2 Fabry Disease Treatment Market Overview by Type
2.1 Global Fabry Disease Treatment Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Fabry Disease Treatment Historic Market Size by Type (2015-2020)
2.3 Global Fabry Disease Treatment Forecasted Market Size by Type (2021-2026)
2.4 Enzyme Replacement Therapy (ERT)
2.5 Chaperone Treatment
2.6 Substrate Reduction Therapy (SRT)
2.7 Others
3 Fabry Disease Treatment Market Overview by Application
3.1 Global Fabry Disease Treatment Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Fabry Disease Treatment Historic Market Size by Application (2015-2020)
3.3 Global Fabry Disease Treatment Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Others
4 Global Fabry Disease Treatment Competition Analysis by Players
4.1 Global Fabry Disease Treatment Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fabry Disease Treatment as of 2019)
4.3 Date of Key Manufacturers Enter into Fabry Disease Treatment Market
4.4 Global Top Players Fabry Disease Treatment Headquarters and Area Served
4.5 Key Players Fabry Disease Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Fabry Disease Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi S.A.
5.1.1 Sanofi S.A. Profile
5.1.2 Sanofi S.A. Main Business
5.1.3 Sanofi S.A. Fabry Disease Treatment Products, Services and Solutions
5.1.4 Sanofi S.A. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.1.5 Sanofi S.A. Recent Developments
5.2 Takeda
5.2.1 Takeda Profile
5.2.2 Takeda Main Business
5.2.3 Takeda Fabry Disease Treatment Products, Services and Solutions
5.2.4 Takeda Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.2.5 Takeda Recent Developments
5.3 Amicus Therapeutics Inc.
5.5.1 Amicus Therapeutics Inc. Profile
5.3.2 Amicus Therapeutics Inc. Main Business
5.3.3 Amicus Therapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.3.4 Amicus Therapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.3.5 ISU Abxis Co Ltd. Recent Developments
5.4 ISU Abxis Co Ltd.
5.4.1 ISU Abxis Co Ltd. Profile
5.4.2 ISU Abxis Co Ltd. Main Business
5.4.3 ISU Abxis Co Ltd. Fabry Disease Treatment Products, Services and Solutions
5.4.4 ISU Abxis Co Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.4.5 ISU Abxis Co Ltd. Recent Developments
5.5 JCR Pharmaceuticals Co Ltd.
5.5.1 JCR Pharmaceuticals Co Ltd. Profile
5.5.2 JCR Pharmaceuticals Co Ltd. Main Business
5.5.3 JCR Pharmaceuticals Co Ltd. Fabry Disease Treatment Products, Services and Solutions
5.5.4 JCR Pharmaceuticals Co Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.5.5 JCR Pharmaceuticals Co Ltd. Recent Developments
5.6 Protalix Biotherapeutics Inc.
5.6.1 Protalix Biotherapeutics Inc. Profile
5.6.2 Protalix Biotherapeutics Inc. Main Business
5.6.3 Protalix Biotherapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.6.4 Protalix Biotherapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.6.5 Protalix Biotherapeutics Inc. Recent Developments
5.7 Idorsia Pharmaceuticals Ltd.
5.7.1 Idorsia Pharmaceuticals Ltd. Profile
5.7.2 Idorsia Pharmaceuticals Ltd. Main Business
5.7.3 Idorsia Pharmaceuticals Ltd. Fabry Disease Treatment Products, Services and Solutions
5.7.4 Idorsia Pharmaceuticals Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.7.5 Idorsia Pharmaceuticals Ltd. Recent Developments
5.8 Avrobio Inc.
5.8.1 Avrobio Inc. Profile
5.8.2 Avrobio Inc. Main Business
5.8.3 Avrobio Inc. Fabry Disease Treatment Products, Services and Solutions
5.8.4 Avrobio Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.8.5 Avrobio Inc. Recent Developments
5.9 Greenovation Biotech GmbH
5.9.1 Greenovation Biotech GmbH Profile
5.9.2 Greenovation Biotech GmbH Main Business
5.9.3 Greenovation Biotech GmbH Fabry Disease Treatment Products, Services and Solutions
5.9.4 Greenovation Biotech GmbH Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.9.5 Greenovation Biotech GmbH Recent Developments
5.10 Moderna Therapeutics Inc.
5.10.1 Moderna Therapeutics Inc. Profile
5.10.2 Moderna Therapeutics Inc. Main Business
5.10.3 Moderna Therapeutics Inc. Fabry Disease Treatment Products, Services and Solutions
5.10.4 Moderna Therapeutics Inc. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.10.5 Moderna Therapeutics Inc. Recent Developments
5.11 Green Cross Pharma Pte Ltd.
5.11.1 Green Cross Pharma Pte Ltd. Profile
5.11.2 Green Cross Pharma Pte Ltd. Main Business
5.11.3 Green Cross Pharma Pte Ltd. Fabry Disease Treatment Products, Services and Solutions
5.11.4 Green Cross Pharma Pte Ltd. Fabry Disease Treatment Revenue (US$ Million) & (2015-2020)
5.11.5 Green Cross Pharma Pte Ltd. Recent Developments
6 North America
6.1 North America Fabry Disease Treatment Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Fabry Disease Treatment Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Fabry Disease Treatment Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Fabry Disease Treatment Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Fabry Disease Treatment Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Fabry Disease Treatment Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
